The self-controlled case series method for evaluating safety of vaccines
Authors: Steven Hawken and Kumanan R Wilson
Published online: 19 November 2012
Using cases as their own controls potentially provides stronger evidence for analysing adverse events following vaccination
Maintaining public confidence in vaccines requires having effective postmarketing vaccine safety surveillance systems in place to rapidly address emerging concerns about vaccine safety. However, conducting studies of vaccine safety presents several challenges for traditional observational study designs. Important differences may exist between vaccinated and unvaccinated individuals that could confound the true association of interest between vaccination and adverse events. In practice, it is often difficult or impossible to adequately control statistically for these differences, either because confounders are unmeasured or unmeasureable, or because of the scarcity of unvaccinated controls when studying population-wide immunisation programs.
In this issue of the Journal, Crawford and colleagues used the self-controlled case series (SCCS) method to assess the association between pandemic (H1N1) 2009 influenza vaccination and the occurrence of Guillain-Barré syndrome.1 The SCCS design, which was developed by C Paddy Farrington, has emerged as a gold-standard method for studying adverse events following vaccination.2-6 In contrast to other designs such as cohort and case–control, the SCCS is a case-only design, requiring information only on individuals who have received the exposure (vaccination) and experienced one or more adverse events of interest, thus avoiding problems related to differences between vaccinated and unvaccinated individuals.
In the SCCS design, the observation time for each person is subdivided into exposed (risk) segments where it is biologically plausible that the exposure (vaccination) could cause the event, and unexposed (control) segments where it is biologically implausible that the exposure could cause the event. Each person is, in essence, compared with him- or herself in exposed versus unexposed time periods. This cancels out fixed individual factors (eg, sex, socioeconomic status) and thus completely adjusts for the effect of these potential confounders.3,5 The incidence of events in risk and control periods is calculated by determining the number of events per person/time at risk (ie, events/day). An overall relative incidence (RI) is then calculated by obtaining the ratio of incidence levels in the risk period compared with the control period. In order to calculate valid confidence intervals for RI estimates, statistical modelling is required. The SCCS model can be fitted using a Poisson regression model, which is routinely used to model count data. The Poisson regression is stratified by individual, to allow estimation of the association between intraindividual exposure and adverse events, expressed as an RI, and appropriate confidence limits.5
The observation period for three individuals from a hypothetical SCCS study of febrile seizures following measles –mumps–rubella (MMR) vaccination after children reach 1 year of age is illustrated in the Box. Each child is observed between their first and second birthday (age 365 to 730 days). Febrile seizures are expected to occur within 1–2 weeks following MMR vaccination. For simplicity, we define one risk period — the 14 days immediately following vaccination. The remainder of the observation period before and after the postvaccination risk period is designated as the control period. This simplistic example illustrates the basic method; however, it is easily generalised to multiple exposures, multiple risk periods and adjustment for age and seasonal effects. This would be necessary, for example, if individuals were to receive a second MMR vaccination at 18 months.
The SCCS design has some important limitations. First, like other observational designs, it is susceptible to confounding from coincident temporal exposures (unmeasured exposures that occur during the same observation period as the exposure of interest; for example, a second vaccine given at the same time as the vaccine of interest). Second, also like other observational vaccine safety designs, the SCCS is susceptible to the healthy vaccinee effect, whereby vaccination is deferred for patients in ill health in the week preceding a scheduled vaccination. This results in vaccinated individuals appearing healthy immediately before and after vaccination, potentially washing out effects within the first few days following vaccination.4,7,8 Third, the method is not well suited to situations where the occurrence of events truncates or curtails the duration of the exposure period (eg, death). However, extensions to the model have been developed that address these issues.5,9-11
The SCCS is an important method for studying adverse events following vaccination. It is well suited to use in linked health administrative data and is quick to implement, allowing safety surveillance studies to be undertaken in a short time frame. In many cases, SCCS studies can provide stronger evidence than even a large cohort study, since they provide complete control of individual-level confounders and often have as much, or more, power.3 For more detailed information, we recommend the following website: http://statistics.open.ac.uk/sccs.
Competing interests
No relevant disclosures.
References
- Crawford NW, Cheng A, Andrews N, et al. Guiilain-Barré syndrome following pandemic (H1N1) 2009 influenza A immunisation in Victoria: a self-controlled case series. Med J Aust 2012; 197: 574-578. 0_CHDBCFID
- Andrews NJ. Statistical assessment of the association between vaccination and rare adverse events post-licensure. Vaccine 2001; 20 Suppl 1: S49-S53. 0_i1139903
- Farrington CP. Control without separate controls: evaluation of vaccine safety using case-only methods. Vaccine 2004; 22: 2064-2070. 0_i1139905
- Farrington CP, Pugh S, Colville A, et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet 1995; 345: 567-569. 0_i1139907
- Whitaker HJ, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: the self-controlled case series method. Stat Med 2006; 25: 1768-1797. 0_i1139910
- Weldeselassie YG, Whitaker HJ, Farrington CP. Use of the self-controlled case-series method in vaccine safety studies: review and recommendations for best practice. Epidemiol Infect 2011; 139: 1805-1817. 0_i1139912
- Virtanen M, Peltola H, Paunio M, Heinonen OP. Day-to-day reactogenicity and the healthy vaccinee effect of measles-mumps-rubella vaccination. Pediatrics 2000; 106: E62. 0_i1139914
- Wilson K, Hawken S, Potter BK, et al. Patterns of emergency room visits, admissions and death following recommended pediatric vaccinations - a population based study of 969,519 vaccination events. Vaccine 2011; 29: 3746-3752. 0_i1139916
- Farrington CP, Whitaker HJ, Hocine MN. Case series analysis for censored, perturbed, or curtailed post-event exposures. Biostatistics 2009; 10: 3-16. 0_i1139918
- Kuhnert R, Hecker H, Poethko-Müller C, et al. A modified self-controlled case series method to examine association between multidose vaccinations and death. Stat Med 2010; 30: 666-677. 0_i1139920
- Farrington CP, Whitaker HJ. Semiparametric analysis of case series data. J R Stat Soc Ser C Appl Stat 2006; 55: 553-594. 0_i1139923
Provenance: <p>Commissioned; not externally peer reviewed.</p>
Interpreting Australian Stillbirth Rate Trends: Implications for Surveillance and Continuous Quality Improvement
Aleena M. Wojcieszek, Kirstine Sketcher-Baker, Christine Andrews, Michael Coory, Imogen Kettle, Melissa Malivoire, David Ellwood, Vicki Flenady
Paracetamol in Pregnancy: Uncertain Evidence, Certain Consequences
David J. Tunnicliffe, Miranda Cumpston, Debra Kennedy, Margie Danchin, Armando Teixeira-Pinto
Fatty Liver Disease in Australia: A Narrative Review on the Epidemiology, Natural History, Prognostication and Management in People With Metabolic Dysfunction
Karl Vaz, Daniel Clayton-Chubb, William W. Kemp, Stuart K. Roberts, Ammar Majeed
Birth prevalence, clinical sequelae, and management of congenital cytomegalovirus infections in Australia, 1999–2023: a national prospective study
Ece Egilmezer, Suzy M Teutsch, Carlos Nunez, Stuart T Hamilton, Adam W Bartlett, Pamela Palasanthiran, Elizabeth J Elliott, William D Rawlinson
The number of cancer‐related deaths that could be attributable to spatial disparities in survival in Australia, 2010–2019: a retrospective population‐based cohort study
Charlotte K Bainomugisa, Jessica Cameron, Paramita Dasgupta, Peter Baade
Mandatory research projects during medical specialist training in Australia and New Zealand
Paulina Stehlik, Caitlin Brandenburg, David A Henry
